Management of suspected monogenic lung fibrosis in a specialised centre

European Respiratory Review

Volumn 26, Issue 144, 2017, Pages

  Borie, Raphael ^a,b,c,d   Kannengiesser, Caroline ^b,d   de Fontbrune, Flore Sicre ^e   Gouya, Laurent ^d,f,g,h   Nathan, Nadia ^i,j   Crestani, Bruno ^a,b,c,d  

^a HÔpital Bichat AP HP   (France)

^b BICHAT HOSPITAL   (France)

^c Service de Pneumologie A Département hospitalo universitaire FIRE   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f HÔPITAL LOUIS MOURIER   (France)

^g Laboratory of Excellence   (France)

^h CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

ⁱ ARMAND TROUSSEAU HOSPITAL   (France)

^j INSERM   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

SURFACTANT; TELOMERASE;

AGE; ARTICLE; ASYMPTOMATIC DISEASE; DISEASE COURSE; FAMILIAL DISEASE; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC SCREENING; GERMLINE MUTATION; HEMATOLOGIC DISEASE; HUMAN; INHERITANCE; LIVER DISEASE; LUNG BIOPSY; LUNG FIBROSIS; MONOGENIC DISORDER; PATIENT CARE; PREVALENCE; RISK FACTOR; SKIN MANIFESTATION; TELOMERE LENGTH; THORAX RADIOGRAPHY; TREATMENT PLANNING; X-RAY COMPUTED TOMOGRAPHY; DNA MUTATIONAL ANALYSIS; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; INTERDISCIPLINARY COMMUNICATION; INTERSTITIAL LUNG DISEASE; MUTATION; PATHOPHYSIOLOGY; PATIENT REFERRAL; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; SPECIALIZATION; TREATMENT OUTCOME;

DNA MUTATIONAL ANALYSIS; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; INTERDISCIPLINARY COMMUNICATION; LUNG DISEASES, INTERSTITIAL; MUTATION; PATIENT CARE TEAM; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PULMONARY FIBROSIS; REFERRAL AND CONSULTATION; RISK FACTORS; SPECIALIZATION; TREATMENT OUTCOME;

EID: 85018241994     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.0122-2016     Document Type: Article

References (126)

1. Hodgson U, Laitinen T, Tukiainen P. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax 2002; 57: 338–342.
2. Kropski JA, Pritchett JM, Zoz DF, et al. Extensive phenotyping of individuals at risk for familial interstitial pneumonia reveals clues to the pathogenesis of interstitial lung disease. Am J Respir Crit Care Med 2014; 191: 417–426.
3. Tsakiri KD, Cronkhite JT, Kuan PJ, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA 2007; 104: 7552–7557.
4. Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007; 356: 1317–1326.
5. Stanley SE, Gable DL, Wagner CL, et al. Loss-of-function mutations in the RNA biogenesis factor NAF1 predispose to pulmonary fibrosis-emphysema. Sci Transl Med 2016; 8: 351ra107.
6. Mercier S, Küry S, Shaboodien G, et al. Mutations in FAM111B cause hereditary fibrosing poikiloderma with tendon contracture, myopathy, and pulmonary fibrosis. Am J Hum Genet 2013; 93: 1100–1107.
7. Picard C, Thouvenin G, Kannengiesser C, et al. Severe pulmonary fibrosis as the first manifestation of interferonopathy (TMEM173 mutation). Chest 2016; 150: e65–e71.
8. Watkin LB, Jessen B, Wiszniewski W, et al. COPA mutations impair ER–Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis. Nat Genet 2015; 47: 654–660.
9. Newton CA, Batra K, Torrealba J, et al. Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. Eur Respir J 2016; 48: 1710–1720.
10. Ballerie A, Nimubona S, Meunier C, et al. Association of pulmonary alveolar proteinosis and fibrosis: patient with GATA2 deficiency. Eur Respir J 2016; 48: 1510–1514.
11. Kröner C, Reu S, Teusch V, et al. Genotype alone does not predict the clinical course of SFTPC deficiency in paediatric patients. Eur Respir J 2015; 46: 197–206.
12. Harari S, Madotto F, Caminati A, et al. Epidemiology of idiopathic pulmonary fibrosis in northern Italy. PLoS One 2016; 11: e0147072.
13. Marshall RP, Puddicombe A, Cookson WO, et al. Adult familial cryptogenic fibrosing alveolitis in the United Kingdom. Thorax 2000; 55: 143–146.
14. Loyd JE. Pulmonary fibrosis in families. Am J Respir Cell Mol Biol 2003; 29: Suppl. 3, S47–S50.
15. García-Sancho C, Buendía-Roldán I, Fernández-Plata MR, et al. Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Respir Med 2011; 105: 1902–1907.
16. Steele MP, Speer MC, Loyd JE, et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 2005; 172: 1146–1152.
17. Collopy LC, Walne AJ, Cardoso S, et al. Triallelic and epigenetic-like inheritance in human disorders of telomerase. Blood 2015; 126: 176–184.
18. Scholand MB, Coon H, Wolff R, et al. Use of a genealogical database demonstrates heritability of pulmonary fibrosis. Lung 2013; 191: 475–481.
19. Okamoto T, Miyazaki Y, Tomita M, et al. A familial history of pulmonary fibrosis in patients with chronic hypersensitivity pneumonitis. Respiration 2013; 85: 384–390.
20. Lee HY, Seo JB, Steele MP, et al. High-resolution CT scan findings in familial interstitial pneumonia do not conform to those of idiopathic interstitial pneumonia. Chest 2012; 142: 1577–1583.
21. Leslie KO, Cool CD, Sporn TA, et al. Familial idiopathic interstitial pneumonia: histopathology and survival in 30 patients. Arch Pathol Lab Med 2012; 136: 1366–1376.
22. Ravaglia C, Tomassetti S, Gurioli C, et al. Features and outcome of familial idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 28–36.
23. Fernandez BA, Fox G, Bhatia R, et al. A Newfoundland cohort of familial and sporadic idiopathic pulmonary fibrosis patients: clinical and genetic features. Respir Res 2012; 13: 64.
24. Lee HL, Ryu JH, Wittmer MH, et al. Familial idiopathic pulmonary fibrosis: clinical features and outcome. Chest 2005; 127: 2034–2041.
25. Rosas IO, Ren P, Avila NA, et al. Early interstitial lung disease in familial pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176: 698–705.
26. Calado RT, Young NS. Telomere diseases. N Engl J Med 2009; 361: 2353–2365.
27. Townsley DM, Dumitriu B, Young NS. Bone marrow failure and the telomeropathies. Blood 2014; 124: 2775–2783.
28. Diaz de Leon A, Cronkhite JT, Katzenstein AL, et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS One 2010; 5: e10680.
29. Alder JK, Parry EM, Yegnasubramanian S, et al. Telomere phenotypes in females with heterozygous mutations in the dyskeratosis congenita 1 (DKC1) gene. Hum Mutat 2013; 34: 1481–1485.
30. Fukuhara A, Tanino Y, Ishii T, et al. Pulmonary fibrosis in dyskeratosis congenita with TINF2 gene mutation. Eur Respir J 2013; 42: 1757–1759.
31. Alder JK, Stanley SE, Wagner CL, et al. Exome sequencing identifies mutant TINF2 in a family with pulmonary fibrosis. Chest 2015; 147: 1361–1368.
32. Kannengiesser C, Borie R, Revy P. Pulmonary fibrosis associated with TINF2 gene mutation: is somatic reversion required? Eur Respir J 2014; 44: 269–270.
33. Stuart BD, Choi J, Zaidi S, et al. Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening. Nat Genet 2015; 47: 512–517.
34. Cogan JD, Kropski JA, Zhao M, et al. Rare variants in RTEL1 are associated with familial interstitial pneumonia. Am J Respir Crit Care Med 2015; 191: 646–655.
35. Kannengiesser C, Borie R, Ménard C, et al. Heterozygous RTEL1 mutations are associated with familial pulmonary fibrosis. Eur Respir J 2015; 46: 474–485.
36. Borie R, Tabèze L, Thabut G, et al. Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis. Eur Respir J 2016; 48: 1721–1731.
37. Snetselaar R, van Moorsel CH, Kazemier KM, et al. Telomere length in interstitial lung diseases. Chest 2015; 148: 1011–1018.
38. Gutierrez-Rodrigues F, Santana-Lemos BA, Scheucher PS, et al. Direct comparison of flow-FISH and qPCR as diagnostic tests for telomere length measurement in humans. PLoS One 2014; 9: e113747.
39. Cronkhite JT, Xing C, Raghu G, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 178: 729–737.
40. Haque S, Rakieh C, Marriage F, et al. Shortened telomere length in patients with systemic lupus erythematosus. Arthritis Rheum 2013; 65: 1319–1323.
41. Hou L, Andreotti G, Baccarelli AA, et al. Lifetime pesticide use and telomere shortening among male pesticide applicators in the Agricultural Health Study. Environ Health Perspect 2013; 121: 919–924.
42. Alder JK, Guo N, Kembou F, et al. Telomere length is a determinant of emphysema susceptibility. Am J Respir Crit Care Med 2011; 184: 904–912.
43. Alder JK, Cogan JD, Brown AF, et al. Ancestral mutation in telomerase causes defects in repeat addition processivity and manifests as familial pulmonary fibrosis. PLoS Genet 2011; 7: e1001352.
44. Gansner JM, Rosas IO, Ebert BL. Pulmonary fibrosis, bone marrow failure, and telomerase mutation. N Engl J Med 2012; 366: 1551–1553.
45. Nunes H, Monnet I, Kannengiesser C, et al. Is telomeropathy the explanation for combined pulmonary fibrosis and emphysema syndrome? Report of a family with TERT mutation. Am J Respir Crit Care Med 2014; 189: 753–754.
46. Stanley SE, Chen JJ, Podlevsky JD, et al. Telomerase mutations in smokers with severe emphysema. J Clin Invest 2015; 125: 563–570.
47. Karimi-Shah BA, Chowdhury BA. Forced vital capacity in idiopathic pulmonary fibrosis – FDA review of pirfenidone and nintedanib. N Engl J Med 2015; 372: 1189–1191.
48. El-Chemaly S, Ziegler SG, Calado RT, et al. Natural history of pulmonary fibrosis in two subjects with the same telomerase mutation. Chest 2011; 139: 1203–1209.
49. Justet A, Borie R, Nunes H, et al. Safety and efficacy of pirfenidone in patients with lung fibrosis and TERT mutation. Eur Respir J 2016; 48: Suppl. 60, OA484.
50. Townsley DM, Dumitriu B, Liu D, et al. Danazol treatment for telomere diseases. N Engl J Med 2016; 374: 1922–1931.
51. Bernardes de Jesus B, Schneeberger K, Vera E, et al. The telomerase activator TA-65 elongates short telomeres and increases health span of adult/old mice without increasing cancer incidence. Aging Cell 2011; 10: 604–621.
52. + T lymphocytes. J Immunol 2008; 181: 7400–7406.
53. Dow CT, Harley CB. Evaluation of an oral telomerase activator for early age-related macular degeneration – a pilot study. Clin Ophthalmol 2016; 10: 243–249.
54. Pearce VP, Sherrell J, Lou Z, et al. Immortalization of epithelial progenitor cells mediated by resveratrol. Oncogene 2008; 27: 2365–2374.
55. Babizhayev MA, Yegorov YE. Telomere attrition in lens epithelial cells – a target for N-acetylcarnosine therapy. Front Biosci (Landmark Ed) 2010; 15: 934–956.
56. Eitan E, Tichon A, Gazit A, et al. Novel telomerase-increasing compound in mouse brain delays the onset of amyotrophic lateral sclerosis. EMBO Mol Med 2012; 4: 313–329.
57. Bersani FS, Lindqvist D, Mellon SH, et al. Telomerase activation as a possible mechanism of action for psychopharmacological interventions. Drug Discov Today 2015; 20: 1305–1309.
58. Silhan LL, Shah PD, Chambers DC, et al. Lung transplantation in telomerase mutation carriers with pulmonary fibrosis. Eur Respir J 2014; 44: 178–187.
59. Borie R, Kannengiesser C, Hirschi S, et al. Severe hematologic complications after lung transplantation in patients with telomerase complex mutations. J Heart Lung Transplant 2015; 34: 538–546.
60. Tokman S, Singer JP, Devine MS, et al. Clinical outcomes of lung transplant recipients with telomerase mutations. J Heart Lung Transplant 2015; 34: 1318–1324.
61. George G, Rosas IO, Cui Y, et al. Short telomeres, telomeropathy, and subclinical extrapulmonary organ damage in patients with interstitial lung disease. Chest 2015; 147: 1549–1557.
62. Heiss NS, Knight SW, Vulliamy TJ, et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet 1998; 19: 32–38.
63. Zinsser F. Atrophia Cutis Reticularis cum Pigmentations, Dystrophia Unguium et Leukoplakis oris (Poikioodermia atrophicans vascularis Jacobi). Ikonographia Dermatologica 1910; 5: 219–223.
64. Savage SA, Cook EF. Dyskeratosis Congenita and Telomere Biology Disorders: Diagnosis and Management Guidelines. New York, Dyskeratosis Congenita Outreach, Inc., 2015. www.dcoutreach.org/sites/default/files/DC%20%26%20TBD%20Diagnosis%20And%20Management%20Guidelines.pdf
65. Langston AA, Sanders JE, Deeg HJ, et al. Allogeneic marrow transplantation for aplastic anaemia associated with dyskeratosis congenita. Br J Haematol 1996; 92: 758–765.
66. Diaz de Leon A, Cronkhite JT, Yilmaz C, et al. Subclinical lung disease, macrocytosis, and premature graying in kindreds with telomerase (TERT) mutations. Chest 2011; 140: 753–763.
67. Ball SE, Gibson FM, Rizzo S, et al. Progressive telomere shortening in aplastic anemia. Blood 1998; 91: 3582–3592.
68. Yamaguchi H, Baerlocher GM, Lansdorp PM, et al. Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood 2003; 102: 916–918.
69. Yamaguchi H, Calado RT, Ly H, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 2005; 352: 1413–1424.
70. Parry EM, Alder JK, Qi X, et al. Syndrome complex of bone marrow failure and pulmonary fibrosis predicts germline defects in telomerase. Blood 2011; 117: 5607–5611.
71. Calado RT, Regal JA, Kleiner DE, et al. A spectrum of severe familial liver disorders associate with telomerase mutations. PLoS One 2009; 4: e7926.
72. Hartmann D, Srivastava U, Thaler M, et al. Telomerase gene mutations are associated with cirrhosis formation. Hepatology 2011; 53: 1608–1617.
73. Gorgy AI, Jonassaint NL, Stanley SE, et al. Hepatopulmonary syndrome is a frequent cause of dyspnea in the short telomere disorders. Chest 2015; 148: 1019–1026.
74. Armanios M, Price C. Telomeres and disease: an overview. Mutat Res 2012; 730: 1–2.
75. Dokal I. Dyskeratosis congenita. Hematology Am Soc Hematol Educ Program 2011; 2011: 480–486.
76. Mialou V, Leblanc T, Peffault de Latour R, et al. La dyskératose congénitale: mise au point [Dyskeratosis congenita: an update]. Arch Pediatr 2013; 20: 299–306.
77. Whitsett JA, Wert SE, Weaver TE. Alveolar surfactant homeostasis and the pathogenesis of pulmonary disease. Annu Rev Med 2010; 61: 105–119.
78. Flamein F, Riffault L, Muselet-Charlier C, et al. Molecular and cellular characteristics of ABCA3 mutations associated with diffuse parenchymal lung diseases in children. Hum Mol Genet 2012; 21: 765–775.
79. Thouvenin G, Abou Taam R, Flamein F, et al. Characteristics of disorders associated with genetic mutations of surfactant protein C. Arch Dis Child 2010; 95: 449–454.
80. Brasch F, Griese M, Tredano M, et al. Interstitial lung disease in a baby with a de novo mutation in the SFTPC gene. Eur Respir J 2004; 24: 30–39.
81. Thouvenin G, Nathan N, Epaud R, et al. Diffuse parenchymal lung disease caused by surfactant deficiency: dramatic improvement by azithromycin. BMJ Case Rep 2013; 2013: bcr2013009988.
82. Wambach JA, Casey AM, Fishman MP, et al. Genotype–phenotype correlations for infants and children with ABCA3 deficiency. Am J Respir Crit Care Med 2014; 189: 1538–1543.
83. Epaud R, Delestrain C, Louha M, et al. Combined pulmonary fibrosis and emphysema syndrome associated with ABCA3 mutations. Eur Respir J 2014; 43: 638–641.
84. Campo I, Zorzetto M, Mariani F, et al. A large kindred of pulmonary fibrosis associated with a novel ABCA3 gene variant. Respir Res 2014; 15: 43.
85. van Moorsel CH, van Oosterhout MF, Barlo NP, et al. Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a Dutch cohort. Am J Respir Crit Care Med 2010; 182: 1419–1425.
86. Mechri M, Epaud R, Emond S, et al. Surfactant protein C gene (SFTPC) mutation-associated lung disease: high-resolution computed tomography (HRCT) findings and its relation to histological analysis. Pediatr Pulmonol 2010; 45: 1021–1029.
87. Ono S, Tanaka T, Ishida M, et al. Surfactant protein C G100S mutation causes familial pulmonary fibrosis in Japanese kindred. Eur Respir J 2011; 38: 861–869.
88. Cottin V, Reix P, Khouatra C, et al. Combined pulmonary fibrosis and emphysema syndrome associated with familial SFTPC mutation. Thorax 2011; 66: 918–919.
89. Kroner C, Wittmann T, Reu S, et al. Lung disease caused by ABCA3 mutations. Thorax 2017; 72: 213–220.
90. Wang Y, Kuan PJ, Xing C, et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet 2009; 84: 52–59.
91. Coghlan MA, Shifren A, Huang HJ, et al. Sequencing of idiopathic pulmonary fibrosis-related genes reveals independent single gene associations. BMJ Open Respir Res 2014; 1: e000057.
92. Nathan N, Borie R, Kannengiesser C, et al. Genetic testing in idiopathic interstitial pneumonia. Eur Respir J 2015; 46: Suppl. 59, PA4849.
93. Hamvas A, Deterding RR, Wert SE, et al. Heterogeneous pulmonary phenotypes associated with mutations in the thyroid transcription factor gene NKX2-1. Chest 2013; 144: 794–804.
94. Santiago Borrero PJ, Rodríguez-Pérez Y, Renta JY, et al. Genetic testing for oculocutaneous albinism type 1 and 2 and Hermansky–Pudlak syndrome type 1 and 3 mutations in Puerto Rico. J Invest Dermatol 2006; 126: 85–90.
95. Liu Y, Jesus AA, Marrero B, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med 2014; 371: 507–518.
96. Girerd B, Coulet F, Jaïs X, et al. Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of bone morphogenetic protein receptor type 2. Chest 2015; 147: 1385–1394.
97. Huizing M, Helip-Wooley A, Westbroek W, et al. Disorders of lysosome-related organelle biogenesis: clinical and molecular genetics. Annu Rev Genomics Hum Genet 2008; 9: 359–386.
98. Gahl WA, Brantly M, Kaiser-Kupfer MI, et al. Genetic defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky–Pudlak syndrome). N Engl J Med 1998; 338: 1258–1264.
99. Pierson DM, Ionescu D, Qing G, et al. Pulmonary fibrosis in Hermansky–Pudlak syndrome. A case report and review. Respiration 2006; 73: 382–395.
100. Jeremiah N, Neven B, Gentili M, et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J Clin Invest 2014; 124: 5516–5520.
101. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011; 364: 1503–1512.
102. Borie R, Crestani B, Dieude P, et al. The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population. PLoS One 2013; 8: e70621.
103. Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet 2013; 45: 613–620.
104. Noth I, Zhang Y, Ma SF, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med 2013; 1: 309–317.
105. Horimasu Y, Ohshimo S, Bonella F, et al. MUC5B promoter polymorphism in Japanese patients with idiopathic pulmonary fibrosis. Respirology 2015; 20: 439–444.
106. Oldham JM, Ma SF, Martinez FJ, et al. TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2015; 192: 1475–1482.
107. Kropski JA, Young LR, Cogan JD, et al. Genetic evaluation and testing of patients and families with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2016; in press [https://doi.org/10.1164/rccm.201609-1820PP].
108. Chung JH, Peljto AL, Chawla A, et al. CT imaging phenotypes of pulmonary fibrosis in the MUC5B promoter site polymorphism. Chest 2016; 149: 1215–1222.
109. Cottin V, Crestani B, Valeyre D, et al. Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique. Élaborées par le centre national de référence et les centres de compétence pour les maladies pulmonaires rares sous l’égide de la Société de Pneumologie de Langue Française. [French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis. From the National Reference and the Competence centers for rare diseases and the Société de pneumologie de langue française.] Rev Mal Respir 2013; 30: 879–902.
110. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824.
111. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733–748.
112. Cottin V, Crestani B, Valeyre D, et al. Diagnosis and management of idiopathic pulmonary fibrosis: French practical guidelines. Eur Respir Rev 2014; 23: 193–214.
113. Nathan N, Borie R, Kannengiesser C, et al. Contribution of mutations in genes encoding proteins of the surfactant metabolism to idiopathic interstitial pneumonia and idiopathic pulmonary fibrosis in a cohort of 265 families. Am J Respir Cell Mol Biol 2016; 193: A2605.
114. Haute Autorité de Santé. Règles de bonnes pratiques en génétique constitutionnelle à des fins médicales (Hors diagnostic prénatal). [Rules of good practice in constitutional genetics for medical purposes (excluding prenatal diagnosis).] www.has-sante.fr/portail/upload/docs/application/pdf/2013-02/regles_de_bonne_pratique_en_genetique_ constitutionnelle_a_des_fins_medicales.pdfDate last updated: February 20, 2013. Date last accessed: March 30, 2017.
115. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405–424.
116. Claustres M, Kožich V, Dequeker E, et al. Recommendations for reporting results of diagnostic genetic testing (biochemical, cytogenetic and molecular genetic). Eur J Hum Genet 2014; 22: 160–170.
117. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009; 461: 747–753.
118. McCarthy MI, Abecasis GR, Cardon LR, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 2008; 9: 356–369.
119. Borie R, Kannengiesser C, Nathan N, et al. Genetics. In: Costabel U, Crestani B, Wells AU, eds. Idiopathic Pulmonary Fibrosis (ERS Monograph). Sheffield, European Respiratory Society, 2016; pp. 16–34.
120. Kropski JA, Mitchell DB, Markin C, et al. A novel dyskerin (DKC1) mutation is associated with familial interstitial pneumonia. Chest 2014; 146: e1–e7.
121. Nathan N, Giraud V, Picard C, et al. Germline SFTPA1 mutation in familial idiopathic interstitial pneumonia and lung cancer. Hum Mol Genet 2016; 25: 1457–1467.
122. Wegner DJ, Hertzberg T, Heins HB, et al. A major deletion in the surfactant protein-B gene causing lethal respiratory distress. Acta Paediatr 2007; 96: 516–520.
123. Cottin V, Cordier JF. SFTPC mutations in patients with familial pulmonary fibrosis: combined with emphysema? Am J Respir Crit Care Med 2011; 183: 1113.
124. Montani D, Coulet F, Girerd B, et al. Pulmonary hypertension in patients with neurofibromatosis type I. Medicine (Baltimore) 2011; 90: 201–211.
125. O’Brien K, Troendle J, Gochuico BR, et al. Pirfenidone for the treatment of Hermansky–Pudlak syndrome pulmonary fibrosis. Mol Genet Metab 2011; 103: 128–134.
126. Hartmannova H, Piherova L, Tauchmannova K, et al. Acadian variant of Fanconi syndrome is caused by mitochondrial respiratory chain complex I deficiency due to a non-coding mutation in complex I assembly factor NDUFAF6. Hum Mol Genet 2016; 25: 4062–4079.